Risk Factors for Inadequate Bowel Preparation Before Colonoscopy

The project is divided into three key phases:

• Initiation Phase:

Develop a Bowel Preparation Assessment Questionnaire (BPAQ) to standardize data collection.

Establish collaborative centers (multicenter hospitals) nationwide for coordinated implementation.

• Implementation Phase:

Conduct on-site audits to evaluate bowel preparation practices across participating centers.

Deliver protocol-specific training to healthcare providers, emphasizing compliance with the 2023 guidelines.

Systematically collect bowel preparation data, including patient demographics, protocol adherence metrics, and clinical outcomes.

• Conclusion Phase:

Prioritize data quality assurance through dual-entry validation and logic checks to ensure authenticity, comprehensiveness, and objectivity.

Generate consolidated reports to identify systemic gaps and propose evidence-based optimization strategies.

Inclusion criteria

• Patients aged >18 years, regardless of gender, scheduled for colonoscopy
• Written informed consent has been obtained

Exclusion criteria

• History of acute myocardial infarction (within 6 months), severe cardiac/hepatic/renal insufficiency, or psychiatric disorders
• Current use of anticoagulants (e.g., aspirin, warfarin) or presence of coagulation disorders
• Pregnancy or lactation;
• History of inflammatory bowel disease or acute intestinal infection within the past 2 weeks;
• History of colorectal cancer, familial adenomatous polyposis (FAP), or Peutz-Jeghers syndrome;
• History of intestinal obstruction, perforation, stricture, or other conditions precluding completion of colonoscopy;
• Non-compliance with bowel preparation protocols (e.g., ingestion of <80% of prescribed polyethylene glycol (PEG) electrolyte solution);
• Severe hearing impairment, cognitive dysfunction, or inability to cooperate with the study;
• Prior enrollment in this study with a repeat colonoscopy appointment;
• Current participation in other clinical trials or participation in any trial within the preceding 60 days;
• Refusal to provide written informed consent.